Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Low Dose Budesonide
DRUG: High Dose Budesonide
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.